Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004.
about
Treatment of hypertension in peripheral arterial diseaseCritical Limb Ischemia: Current Trends and Future DirectionsPeripheral Arterial Disease in Patients with Type 2 Diabetes MellitusThe impact of omega-3 polyunsaturated fatty acid supplementation on the incidence of cardiovascular events and complications in peripheral arterial disease: a systematic review and meta-analysisParticipation in the Vascular Quality Initiative is associated with improved perioperative medication use, which is associated with longer patient survivalSpectral improvement by fourier thresholding of in vivo dynamic spectroscopy dataCritical evaluation of stents in the peripheral arterial disease of the superficial femoral artery - focus on the paclitaxel eluting stentVascular quality of care pilot study: how admission to a vascular surgery service affects evidence-based pharmacologic risk factor modification in patients with lower extremity peripheral arterial diseaseHypoxia-induced miR-210 modulates tissue response to acute peripheral ischemia.Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease.Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men.Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registrySocioeconomic inequality and peripheral artery disease prevalence in US adultsPerioperative management with antiplatelet and statin medication is associated with reduced mortality following vascular surgery.Profile of atherosclerotic risk factors and management in patients of peripheral arterial disease at a tertiary care teaching hospital of north India.β2-microglobulin, cystatin C, and creatinine and risk of symptomatic peripheral artery disease.Adherence to guideline-recommended therapies among patients with diverse manifestations of vascular disease.Peripheral arterial disease, prevalence and cumulative risk factor profile analysis.Multidisciplinary approach to the diagnosis and management of patients with peripheral arterial disease.Incidence of peripheral arterial disease in the ARTPER population cohort after 5 years of follow-up.A Population-Based Cohort Study on Peripheral Arterial Disease in Patients with Schizophrenia.Atrial Fibrillation Increases the Risk of Peripheral Arterial Disease With Relative Complications and Mortality: A Population-Based Cohort Study.Distribution of Ankle-Brachial Index among Inpatients with Cardiovascular Disease: Analysis Using the Kumamoto University Hospital Medical Database.Immediate results and long-term cardiovascular outcomes of endovascular therapy in octogenarians and nonoctogenarians with peripheral arterial diseases.Vascular protection in patients with diabetes admitted for vascular surgery in a canadian tertiary care hospital: pilot study.Effect of surgical treatment on lipid peroxidation parameters and antioxidant status in the serum of patients with peripheral arterial diseaseCardiac rehabilitation past, present and future: an overview.Socioeconomic disparities in the use of cardioprotective medications among patients with peripheral artery disease: an analysis of the American College of Cardiology's NCDR PINNACLE Registry.Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia.Economic analysis of endovascular interventions for femoropopliteal arterial disease: a systematic review and budget impact model for the United States and Germany.Ticagrelor for the treatment of peripheral arterial disease.Overcoming disease-induced growth factor resistance in therapeutic angiogenesis using recombinant co-receptors delivered by a liposomal system.Drug-coated balloons: how should we incorporate into our practice in treating superficial femoral artery lesions?Drug-coated balloon treatment for lower extremity vascular disease intervention: an international positioning document.Antithrombotic Therapy After Peripheral Vascular Intervention.Underuse of Prevention and Lifestyle Counseling in Patients With Peripheral Artery Disease.Medical Therapy in Peripheral Artery Disease and Critical Limb Ischemia.Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program.Pathophysiology of peripheral arterial disease in diabetes mellitus.2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
P2860
Q24201969-18AEC069-9C28-4299-9F1E-313284308BD9Q26767021-BD49CFCF-8CDD-4B88-8965-86BB6DD58530Q26795374-22AE9E69-F782-4898-A658-DCA19DA40EF7Q26852020-FB8F9C02-B076-4865-9188-F229A4989EDBQ30300929-377E051F-80E7-49C4-9223-CFB98B4F740FQ31002574-4F921E15-9454-4225-A6FE-40846EA92E42Q33710114-72601028-291E-47B2-A4AA-050A0F357E2AQ33734682-7A88586B-9349-4F40-8A3E-C5E8B3415B33Q34082176-6F1EC91B-BA5D-47C0-A3C6-81B9349CDD68Q34297015-BECF4CDA-351B-4D77-85E2-0BFB536FE754Q34307833-BCD01D6C-F3CB-4620-8FF4-5852B10E49C0Q34436787-0D5EA1F8-B75C-4E41-B78F-4F3F42C46EB0Q34448085-E934E9BE-920A-4098-964C-008456DFC936Q34786069-369F0DEF-E685-415A-B152-DAC7FA9CC82FQ34949365-AB35775A-34DB-4441-912C-13EB4C3CCEE5Q35026210-7B8E166A-9E43-43A6-A4AF-DA3F8A927B61Q35161671-BE5BA43C-69EF-418B-83F2-D98280C7B953Q35621575-CE351F1A-DE0F-4951-A11D-F827E4020C4CQ35857344-E26CD115-E78D-485C-B476-9F7BCAEEF208Q35891920-CCF97FEF-698E-4923-A221-2C912820E5DDQ35922175-25CED257-F4DA-47F6-8A70-61CF7E617652Q36664113-C4FC2DF3-290B-4CCD-B6B6-8A2933F6C5FBQ36727255-575D5B02-072B-418C-AC63-7F82626E0115Q36888670-425B21A8-7C2C-4C69-BAEE-AC9961D9A8FAQ37096138-36EB0F9D-8CC4-46BE-9C24-07B8819F5B9BQ37327098-DD6C98EC-CB37-4B60-8E66-0E509E8F7275Q37339354-B9ACC378-2004-4E6D-8E3E-D565CA4A02DCQ37548979-FC67C148-F615-43E5-A250-A4B8483B49B4Q37620353-610D7DD8-364C-4142-B70B-A7BA0ADE2CC6Q38208287-9678906D-B86D-413A-8BDE-43B9DBB0F776Q38265669-4C71507C-0467-47A8-A550-178AA8D04DFDQ38311837-EEA8C0C7-9B45-450B-B6FB-2CCC8E27F273Q38386381-A3FA41F4-C395-46F2-BB7A-242D836027AAQ38502277-410CE38C-D589-4BBA-AD31-A5D0ABCDEA4BQ38721851-7D9FA895-788E-4396-B8E3-0A05C1EA409DQ38803492-DCD9C9F2-6394-470E-9DEF-B2A16CAF299BQ38834990-A61F316B-8731-4E3D-B68C-0D83A0F97AB1Q38869502-BE046E74-98B9-477F-A64C-30B2524640AFQ38936026-5AA4B1F6-2322-4DBB-AE19-7E422FD6BFBBQ39007230-A774FBD4-B848-416E-8E74-7832F0596A67
P2860
Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Secondary prevention and morta ...... amination Study, 1999 to 2004.
@ast
Secondary prevention and morta ...... amination Study, 1999 to 2004.
@en
type
label
Secondary prevention and morta ...... amination Study, 1999 to 2004.
@ast
Secondary prevention and morta ...... amination Study, 1999 to 2004.
@en
prefLabel
Secondary prevention and morta ...... amination Study, 1999 to 2004.
@ast
Secondary prevention and morta ...... amination Study, 1999 to 2004.
@en
P2093
P2860
P1433
P1476
Secondary prevention and morta ...... amination Study, 1999 to 2004.
@en
P2093
Joshua A Beckman
Mark A Creager
Reena L Pande
Todd S Perlstein
P2860
P356
10.1161/CIRCULATIONAHA.110.003954
P407
P577
2011-06-20T00:00:00Z